News
Lorlatinib as an Alternative to CNS Radiotherapy in Patients with NSCLC − Case Studies
Two remarkable case studies from authors at the Netherlands Cancer Institute Antoni van Leeuwenhoek in Amsterdam present patients with advanced NSCLC with metastatic CNS involvement. Treatment with crizotinib led to good control of pulmonary involvement but did not affect metastatic CNS involvement. The introduction of lorlatinib subsequently led to rapid improvement in neurological symptoms, which was also confirmed by CNS imaging.
Idarucizumab reverses the anticoagulant effect of dabigatran even in patients with impaired renal function – clinical practice commentary
Along with the results of a subanalysis of the RE-VERSE AD study, which demonstrated the efficacy…
Does The Use of Levothyroxine in Women with Thyroid Peroxidase Antibodies Affect The Risk of Miscarriage and Premature Birth?
Women with thyroid peroxidase antibodies have a higher risk of miscarriage and premature birth,…
Comparison of Clinical Outcomes of TKA Implantation: ATTUNE vs. SIGMA
The ATTUNE total knee arthroplasty (TKA) system was introduced to the market in 2013 as a successor…
Clinical Benefit of Mucolytics in the Treatment of Upper Respiratory Tract Infections
A new review based on published controlled and observational studies as well as real-world practice…
Prevalence and Incidence of Age-Related Macular Degeneration in Europe – Current Overview and Trend Analysis
A comprehensive review article by authors from Bonn, Germany, published late last year in the…
Changes in Intestinal Microflora Correlate with Disease Activity in Patients with Lupus Erythematosus
The role of intestinal microflora in the pathogenesis of autoimmune diseases, including lupus…
Risk Factors and Therapy of Chronic Leg Ulcers Lasting More Than 6 Months
The therapy of chronic leg ulcers in diabetics continues to be a significant challenge for attending...
LDL cholesterol: a new risk factor for the onset of venous thromboembolic disease?
Not only do atherosclerotic plaques in the arteries and the risk of heart attack decrease along…
Polatuzumab Vedotin in Combination Treatment of Patients with R/R DLBCL
Polatuzumab Vedotin is a conjugate of a cytostatic agent and an antibody against CD79b, a component…
Conferences
News from the world of medicine
All conferences
Popular this week
- Good, Bad, or Ugly? What's the Deal with Eggs?
- Intermittent Fasting May Carry Significant Health Risks
- BENIGN DERMATOSIS OF PENIS
- An Orange a Day to Keep Depression Away? The Secret Lies in the Microbiome
- Women who changed medicine: Groundbreaking discoveries even without a Nobel Prize